中华全科医学2024,Vol.22Issue(3) :526-529.DOI:10.16766/j.cnki.issn.1674-4152.003441

维奈克拉联合阿扎胞苷治疗原发性骨髓纤维化转急性巨核细胞白血病1例并文献复习

Venetoclax combined with azacitidine in treatment of acute megakaryoblastic leukemia transformed from primary myelofibrosis:report of 1 case and review of literature

魏小芳 冯友繁 丁国胜 伏媛 陈阳 张启科
中华全科医学2024,Vol.22Issue(3) :526-529.DOI:10.16766/j.cnki.issn.1674-4152.003441

维奈克拉联合阿扎胞苷治疗原发性骨髓纤维化转急性巨核细胞白血病1例并文献复习

Venetoclax combined with azacitidine in treatment of acute megakaryoblastic leukemia transformed from primary myelofibrosis:report of 1 case and review of literature

魏小芳 1冯友繁 1丁国胜 2伏媛 1陈阳 1张启科1
扫码查看

作者信息

  • 1. 甘肃省人民医院血液科,甘肃兰州 730000
  • 2. 甘肃省人民医院检验科
  • 折叠

摘要

本文回顾性分析甘肃省人民医院1例应用维奈克拉联合阿扎胞苷治疗的原发性骨髓纤维化转化的急性单核细胞白血病老年患者的临床资料,并复习相关文献.本例患者系72岁,男性,诊断原发性骨髓纤维化经芦可替尼治疗2年后转化为急性单核细胞白血病,遂给予维奈克拉联合阿扎胞苷治疗.患者第1疗程后部分缓解,临床症状改善明显.第2疗程后,患者完全缓解,流式微小残留病灶阴性,但持续粒细胞缺乏状态长达45 d,最终因感染死亡.

Abstract

We retrospectively analyzed the clinical data of an elderly patient of acute megakaryoblastic leukemia trans-formed from primary myelofibrosis treated with venetoclax combined with azacitidine in Gansu Provincial People's Hospi-tal and reviewed the relevant literature.This patient,a 72-year-old man,was diagnosed with primary myelofibrosis and was transformed to acute megakaryoblastic leukemia after 2 years of treatment with ruxolitinib,then given venetoclax com-bined with azacitidine.After the first course of treatment,the patient had partial remission of bone marrow and clinical improvement significantly.After the second course of treatment,although the bone marrow had complete remission and flow minimal residual disease(MRD)was negative,agranulocytosis persisted for up to 45 days and finally died due to in-fection.

关键词

维奈克拉/阿扎胞苷/原发性骨髓纤维化/急性巨核细胞白血病

Key words

Venetoclax/Azacitidine/Primary myelofibrosis/Acute megakaryoblastic leukemia

引用本文复制引用

基金项目

甘肃省人民医院院内科研项目(18GSSY4-34)

甘肃省自然科学基金(22JR5RA660)

出版年

2024
中华全科医学
中华预防医学会,安徽省全科医学会

中华全科医学

CSTPCD
影响因子:1.688
ISSN:1674-4152
参考文献量24
段落导航相关论文